 PALO ALTO, Calif., April 22, 2021 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq:EIGR, a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Kim Sablich to its Board of Directors. 